Form 4: Rhythm Pharma CHRO Awarded Equity Compensation

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, received grants of 11,650 restricted stock units and 17,500 stock options.

Summary

• Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), was granted equity awards.
• The awards include 11,650 Restricted Stock Units (RSUs) with a transaction date of February 11, 2026.
• These RSUs vest as to 25% of the total shares on February 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030.
• The awards also include 17,500 Stock Options with an exercise price of $98.47, granted on February 11, 2026.
• The stock options vest and become exercisable in 16 substantially equal installments upon completion of each three full months of successive service following the grant date.
• The stock options have an expiration date of February 10, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation that aligns management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The equity awards align the Chief Human Resources Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The grant of restricted stock units and stock options is a standard component of executive compensation packages, reflecting ongoing commitment to the company.

Negatives

• The awards do not represent an immediate cash benefit to the reporting person, as they are subject to vesting schedules.
• The value of the awards is contingent on the future performance of Rhythm Pharmaceuticals' stock price.

Risks

• The value of the equity awards is subject to market fluctuations in Rhythm Pharmaceuticals' common stock.
• The awards may be forfeited if the reporting person's employment with the Issuer terminates before the vesting conditions are met.

Future Outlook

The filing indicates future vesting schedules for the granted restricted stock units and stock options, contingent on continued service to the Issuer.

Industry Context

StockSavvy.ai notes that equity compensation, including restricted stock units and stock options, is a prevalent practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This grant is consistent with typical compensation structures for Chief Human Resources Officers in publicly traded companies.

Related Party Transactions

• The transaction involves the grant of equity awards to an executive officer, which is a common form of related-party compensation.

Stakeholder Impact

• Shareholders: The equity awards aim to align the Chief Human Resources Officer's long-term interests with those of shareholders, potentially leading to improved company performance and retention of key talent.
• Employees: The compensation structure for a senior executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• Continued service by Pamela J. Cramer to trigger vesting of stock options in 16 substantially equal installments upon completion of each three full months of service.
• Vesting of 25% of Restricted Stock Units on February 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Award, Pamela J. Cramer, Chief Human Resources Officer, Compensation